A new study led by researchers at the UCLA Health Jonsson Comprehensive Cancer Center has found that many cases of high-risk nonmetastatic hormone-sensitive prostate cancer may be more advanced than previously thought.
Risk Adjusted Net Present Value: What is the current valuation of 180 Life Sciences’s Fibrosis and anti-TNF
The revenue for Fibrosis and anti-TNF is expected to reach an annual total of $140 mn by 2037 globally based off GlobalData’s Expiry Model. The